Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: A report from the International Late Effects of Childhood Cancer Guideline Harmonization Group

The Lancet Oncology

Volumn 16, Issue 3, 2015, Pages e123-e136

  Armenian, Saro H ^a   Hudson, Melissa M ^b   Mulder, Renee L ^c   Chen, Ming Hui ^d   Constine, Louis S ^e   Dwyer, Mary ^f   Nathan, Paul C ^g   Tissing, Wim J E ^h   Shankar, Sadhna ⁱ   Sieswerda, Elske ^c   Skinner, Rod ^j   Steinberger, Julia ^k   van Dalen, Elvira C ^c   van der Pal, Helena ^c   Wallace, W Hamish ^l   Levitt, Gill ^m   Kremer, Leontien C M ^c  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c EMMA CHILDREN S HOSPITAL   (Netherlands)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^f PETER MACCALLUM CANCER CENTRE   (Australia)

^g HOSPITAL FOR SICK CHILDREN   (Canada)

^h UNIVERSITY OF GRONINGEN   (Netherlands)

ⁱ CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^j Infectious Diseases Allergy   (United Kingdom)

^k UNIVERSITY OF MINNESOTA   (United States)

^l ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^m GREAT ORMOND STREET HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; DAUNORUBICIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; EPIRUBICIN; IDARUBICIN; MITOXANTRONE; RAZOXANE; TROPONIN I; TROPONIN T; ANTINEOPLASTIC ANTIBIOTIC; BIOLOGICAL MARKER;

ACUTE CORONARY SYNDROME; ANGIOGRAPHY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER SURVIVOR; CARDIOLOGIST; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR RISK; CHILDHOOD CANCER; CONGESTIVE HEART FAILURE; DEFIBRILLATION; DISEASE SURVEILLANCE; ECHOCARDIOGRAPHY; EVIDENCE BASED MEDICINE; HEART INJURY; HIGH RISK POPULATION; HUMAN; LIFESTYLE MODIFICATION; LOW RISK POPULATION; MEDICAL SOCIETY; PATIENT MONITORING; PHYSICAL ACTIVITY; PHYSICAL CAPACITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIATION INJURY; REVIEW; RISK ASSESSMENT; RISK FACTOR; ADULT; ADVERSE EFFECTS; AGE; BLOOD; CARDIOMYOPATHIES; CHEMICALLY INDUCED; CHILD; CONSENSUS; COOPERATION; DIAGNOSTIC IMAGING; EARLY DIAGNOSIS; INTERNATIONAL COOPERATION; NEOPLASMS; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; PRESCHOOL CHILD; RADIATION INJURIES; RADIONUCLIDE VENTRICULOGRAPHY; STANDARDS; SURVIVOR; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AGE FACTORS; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; BIOMARKERS; CARDIOMYOPATHIES; CHILD; CHILD, PRESCHOOL; CONSENSUS; COOPERATIVE BEHAVIOR; DIAGNOSTIC IMAGING; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; EVIDENCE-BASED MEDICINE; HUMANS; INTERNATIONAL COOPERATION; MAGNETIC RESONANCE IMAGING; NEOPLASMS; PREDICTIVE VALUE OF TESTS; RADIATION INJURIES; RADIONUCLIDE ANGIOGRAPHY; RADIOTHERAPY; RISK ASSESSMENT; RISK FACTORS; SURVIVORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84924860655     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70409-7     Document Type: Review

References (109)

1. Ries L, Eisner M, Kosary C, et al. Cancer Statistics Review, 1975-2005 2008, National Cancer Institute, Bethesda, MD, (accessed Dec 15, 2013). http://seer.cancer.gov/csr/1975_2005/.
2. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006, 355:1572-1582. the Childhood Cancer Survivor Study.
3. Armstrong GT, Kawashima T, Leisenring W, et al. Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study. J Clin Oncol 2014, 32:1218-1227.
4. Lipshultz SE, Adams MJ, Colan SD, et al. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation 2013, 128:1927-1995. the American Heart Association Congenital Heart Defects Committee of the Council on Cardiovascular Disease in the Young, Council on Basic Cardiovascular SciencesCouncil on Basic Cardiovascular Sciences, Council on Cardiovascular and Stroke NursingCouncil on Cardiovascular and Stroke Nursing, Council on Cardiovascular RadioloCouncil on Cardiovascular Radiolo.
5. Armstrong GT, Liu Q, Yasui Y, et al. Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. J Clin Oncol 2009, 27:2328-2338.
6. Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 2009, 339:b4606.
7. van Dalen EC, van der Pal HJ, Kok WE, Caron HN, Kremer LC Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study. Eur J Cancer 2006, 42:3191-3198.
8. Pein F, Sakiroglu O, Dahan M, et al. Cardiac abnormalities 15 years and more after adriamycin therapy in 229 childhood survivors of a solid tumour at the Institut Gustave Roussy. Br J Cancer 2004, 91:37-44.
9. Hudson MM, Ness KK, Gurney JG, et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA 2013, 309:2371-2381.
10. Landier W, Armenian SH, Lee J, et al. Yield of screening for long-term complications using the children's oncology group long-term follow-up guidelines. J Clin Oncol 2012, 30:4401-4408.
11. Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009, 53:e1-90. the American College of Cardiology Foundation, the American Heart Associationthe American Heart Association.
12. Adams MJ, Lipshultz SE Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention. Pediatr Blood Cancer 2005, 44:600-606.
13. Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent and Young Adult Cancers 2008, Children's Oncology Group, Children's Oncology Group, Arcadia, CA. 3.0 ed.
14. Sieswerda E, Postma A, van Dalen EC, et al. The Dutch Childhood Oncology Group guideline for follow-up of asymptomatic cardiac dysfunction in childhood cancer survivors. Ann Oncol 2012, 23:2191-2198. the Late Effects of Childhood Cancer task force of the Dutch Childhood Oncology Group (DCOG LATER).
15. Therapy based long term follow up practice statement United Kingdom Children's Cancer Study Group Late Effects Group, (accessed June 15, 2013). http://www.cclg.org.uk.
16. Wallace WH, Thompson L, Anderson RA Long term follow-up of survivors of childhood cancer: summary of updated SIGN guidance. BMJ 2013, 346:f1190. the Guideline Development Group.
17. Kremer LC, Mulder RL, Oeffinger KC, et al. A worldwide collaboration to harmonize guidelines for the long-term follow-up of childhood and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Pediatr Blood Cancer 2013, 60:543-549. the International Late Effects of Childhood Cancer Guideline Harmonization Group.
18. Kremer LC, van der Pal HJ, Offringa M, van Dalen EC, VoÛte PA Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol 2002, 13:819-829.
19. Kremer LC, van Dalen EC, Offringa M, VoÛte PA Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review. Ann Oncol 2002, 13:503-512.
20. Lauer MS, Larson MG, Levy D Gender-specific reference M-mode values in adults: population-derived values with consideration of the impact of height. J Am Coll Cardiol 1995, 26:1039-1046.
21. Hudson MM, Rai SN, Nunez C, et al. Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors. J Clin Oncol 2007, 25:3635-3643.
22. Pettersen MD, Du W, Skeens ME, Humes RA Regression equations for calculation of z scores of cardiac structures in a large cohort of healthy infants, children, and adolescents: an echocardiographic study. J Am Soc Echocardiogr 2008, 21:922-934.
23. Fischer M, Baessler A, Hense HW, et al. Prevalence of left ventricular diastolic dysfunction in the community. Results from a Doppler echocardiographic-based survey of a population sample. Eur Heart J 2003, 24:320-328.
24. Gibbons RJ, Smith S, Antman E American College of Cardiology/American Heart Association clinical practice guidelines: Part I: where do they come from?. Circulation 2003, 107:2979-2986. the American College of Cardiology, the American Heart Associationthe American Heart Association.
25. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ 2004, 328:1490. the GRADE Working Group.
26. van der Pal HJ, van Dalen EC, van Delden E, et al. High risk of symptomatic cardiac events in childhood cancer survivors. J Clin Oncol 2012, 30:1429-1437.
27. Blanco JG, Sun CL, Landier W, et al. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes-a report from the Children's Oncology Group. J Clin Oncol 2012, 30:1415-1421.
28. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 2005, 23:2629-2636.
29. van der Pal HJ, van Dalen EC, Hauptmann M, et al. Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study. Arch Intern Med 2010, 170:1247-1255.
30. Temming P, Qureshi A, Hardt J, et al. Prevalence and predictors of anthracycline cardiotoxicity in children treated for acute myeloid leukaemia: retrospective cohort study in a single centre in the United Kingdom. Pediatr Blood Cancer 2011, 56:625-630.
31. Sorensen K, Levitt GA, Bull C, Dorup I, Sullivan ID Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study. Cancer 2003, 97:1991-1998.
32. van Dalen EC, Michiels EM, Caron HN, Kremer LC Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev 2010, 5. CD005006.
33. Schellong G, Riepenhausen M, Bruch C, et al. Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies. Pediatr Blood Cancer 2010, 55:1145-1152.
34. van der Pal HJ, van Dalen EC, Kremer LC, Bakker PJ, van Leeuwen FE Risk of morbidity and mortality from cardiovascular disease following radiotherapy for childhood cancer: a systematic review. Cancer Treat Rev 2005, 31:173-185.
35. Brouwer CA, Postma A, Vonk JM, et al. Systolic and diastolic dysfunction in long-term adult survivors of childhood cancer. Eur J Cancer 2011, 47:2453-2462.
36. Abosoudah I, Greenberg ML, Ness KK, Benson L, Nathan PC Echocardiographic surveillance for asymptomatic late-onset anthracycline cardiomyopathy in childhood cancer survivors. Pediatr Blood Cancer 2011, 57:467-472.
37. Armenian SH, Sun CL, Kawashima T, et al. Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS). Blood 2011, 118:1413-1420.
38. Uderzo C, Pillon M, Corti P, et al. Impact of cumulative anthracycline dose, preparative regimen and chronic graft-versus-host disease on pulmonary and cardiac function in children 5 years after allogeneic hematopoietic stem cell transplantation: a prospective evaluation on behalf of the EBMT Pediatric Diseases and Late Effects Working Parties. Bone Marrow Transplant 2007, 39:667-675.
39. Lönnerholm G, Arvidson J, Andersson LG, Carlson K, Jonzon A, Sunnegårdh J Myocardial function after autologous bone marrow transplantation in children: a prospective long-term study. Acta Paediatr 1999, 88:186-192.
40. Armstrong GT, Oeffinger KC, Chen Y, et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol 2013, 31:3673-3680.
41. Armenian SH, Sun CL, Vase T, et al. Cardiovascular risk factors in hematopoietic cell transplantation survivors: role in development of subsequent cardiovascular disease. Blood 2012, 120:4505-4512.
42. Armstrong GT, Plana JC, Zhang N, et al. Screening adult survivors of childhood cancer for cardiomyopathy: comparison of echocardiography and cardiac magnetic resonance imaging. J Clin Oncol 2012, 30:2876-2884.
43. Erbel R, Schweizer P, Krebs W, Meyer J, Effert S Sensitivity and specificity of two-dimensional echocardiography in detection of impaired left ventricular function. Eur Heart J 1984, 5:477-489.
44. Habash-Bseiso DE, Rokey R, Berger CJ, Weier AW, Chyou PH Accuracy of noninvasive ejection fraction measurement in a large community-based clinic. Clin Med Res 2005, 3:75-82.
45. Rovai D, Morales MA, Di Bella G, et al. Echocardiography and the clinical diagnosis of left ventricular dysfunction. Acta Cardiol 2008, 63:507-513.
46. Postma A, Bink-Boelkens MT, Beaufort-Krol GC, et al. Late cardiotoxicity after treatment for a malignant bone tumor. Med Pediatr Oncol 1996, 26:230-237.
47. Pihkala J, Saarinen UM, Lundström U, et al. Effects of bone marrow transplantation on myocardial function in children. Bone Marrow Transplant 1994, 13:149-155.
48. Mavinkurve-Groothuis AM, Groot-Loonen J, Bellersen L, et al. Abnormal NT-pro-BNP levels in asymptomatic long-term survivors of childhood cancer treated with anthracyclines. Pediatr Blood Cancer 2009, 52:631-636.
49. Kismet E, Varan A, Ayabakan C, Alehan D, Portakal O, Büyükpamukçu M Serum troponin T levels and echocardiographic evaluation in children treated with doxorubicin. Pediatr Blood Cancer 2004, 42:220-224.
50. Sherief LM, Kamal AG, Khalek EA, Kamal NM, Soliman AA, Esh AM Biomarkers and early detection of late onset anthracycline-induced cardiotoxicity in children. Hematology 2012, 17:151-156.
51. Soker M, Kervancioglu M Plasma concentrations of NT-pro-BNP and cardiac troponin-I in relation to doxorubicin-induced cardiomyopathy and cardiac function in childhood malignancy. Saudi Med J 2005, 26:1197-1202.
52. Krawczuk-Rybak M, Dakowicz L, Hryniewicz A, Maksymiuk A, Zelazowska-Rutkowska B, Wysocka J Cardiac function in survivors of acute lymphoblastic leukaemia and Hodgkin's lymphoma. J Paediatr Child Health 2011, 47:455-459.
53. Hayakawa H, Komada Y, Hirayama M, Hori H, Ito M, Sakurai M Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med Pediatr Oncol 2001, 37:4-9.
54. Heidenreich PA, Gubens MA, Fonarow GC, Konstam MA, Stevenson LW, Shekelle PG Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. J Am Coll Cardiol 2004, 43:1019-1026.
55. Bar J, Davidi O, Goshen Y, Hod M, Yaniv I, Hirsch R Pregnancy outcome in women treated with doxorubicin for childhood cancer. Am J Obstet Gynecol 2003, 189:853-857.
56. van Dalen EC, van der Pal HJ, van den Bos C, Kok WE, Caron HN, Kremer LC Clinical heart failure during pregnancy and delivery in a cohort of female childhood cancer survivors treated with anthracyclines. Eur J Cancer 2006, 42:2549-2553.
57. Sieswerda E, van Dalen EC, Postma A, Cheuk DK, Caron HN, Kremer LC Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer. Cochrane Database Syst Rev 2011, 9. CD008011.
58. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008, 10:933-989. the ESC Committee for Practice Guidelines (CPG).
59. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325:293-302. The SOLVD Investigators.
60. Goldberg LR, Jessup M Stage B heart failure: management of asymptomatic left ventricular systolic dysfunction. Circulation 2006, 113:2851-2860.
61. Flather MD, Yusuf S, Køber L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 2000, 355:1575-1581. the ACE-Inhibitor Myocardial Infarction Collaborative Group.
62. Exner DV, Dries DL, Waclawiw MA, Shelton B, Domanski MJ Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1999, 33:916-923.
63. Dargie HJ Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001, 357:1385-1390.
64. Vantrimpont P, Rouleau JL, Wun CC, et al. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. J Am Coll Cardiol 1997, 29:229-236. the SAVE Investigators.
65. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005, 112:e154-e235. the American College of Cardiology, the American Heart Association Task Force on Practice Guidelinesthe American Heart Association Task Force on Practice Guidelines, the American College of Chest Physiciansthe American College of Chest Physicians, the International Society for Heart and Lung Transplantationthe International Society for Heart and Lung Transplantation, the Heart Rhythm Societythe Heart Rhythm Society.
66. Konstam MA, Neaton JD, Poole-Wilson PA, et al. Comparison of losartan and captopril on heart failure-related outcomes and symptoms from the losartan heart failure survival study (ELITE II). Am Heart J 2005, 150:123-131. the ELITE II Investigators.
67. Huang TT, Ness KK Exercise interventions in children with cancer: a review. Int J Pediatr 2011, 2011:461512.
68. Haskell WL, Lee IM, Pate RR, et al. Physical activity and public health: updated recommendation for adults from the American College of Sports Medicine and the American Heart Association. Circulation 2007, 116:1081-1093. the American College of Sports Medicine, the American Heart Associationthe American Heart Association.
69. Thompson PD, Franklin BA, Balady GJ, et al. Exercise and acute cardiovascular events placing the risks into perspective: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism and the Council on Clinical Cardiology. Circulation 2007, 115:2358-2368. the American Heart Association Council on Nutrition, Physical Activity and MetabolismPhysical Activity and Metabolism, the American Heart Association Council on Clinical Cardiologythe American Heart Association Council on Clinical Cardiology, the American College of Sports Medicinethe American College of Sports Medicine.
70. Maron BJ, Chaitman BR, Ackerman MJ, et al. Recommendations for physical activity and recreational sports participation for young patients with genetic cardiovascular diseases. Circulation 2004, 109:2807-2816. the Working Groups of the American Heart Association Committee on Exercise, Cardiac RehabilitationCardiac Rehabilitation, Prevention and the Councils on Clinical Cardiology and Cardiovascular Disease in the YoungPrevention and the Councils on Clinical Cardiology and Cardiovascular Disease in the Young.
71. PPelliccia A, Fagard R, Bjørnstad HH, et al. Recommendations for competitive sports participation in athletes with cardiovascular disease: a consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J 2005, 26:1422-1445. Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology, Working Group of Myocardial and Pericardial Diseases of the European Society of CardiologyWorking Group of Myocardial and Pericardial Diseases of the European Society of Cardiology.
72. Green DM, Grigoriev YA, Nan B, et al. Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study group. J Clin Oncol 2001, 19:1926-1934.
73. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007, 109:1878-1886.
74. van Dalen EC, Caron HN, Dickinson HO, Kremer LC Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2011, 2. CD003917.
75. Lipshultz SE, Scully RE, Lipsitz SR, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol 2010, 11:950-961.
76. Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography-summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). J Am Coll Cardiol 2003, 42:954-970.
77. Janardhanan R, Beller GA Radionuclide imaging in stage B heart failure. Heart Fail Clin 2012, 8:191-206.
78. Ylänen K, Poutanen T, Savikurki-Heikkilä P, Rinta-Kiikka I, Eerola A, Vettenranta K Cardiac magnetic resonance imaging in the evaluation of the late effects of anthracyclines among long-term survivors of childhood cancer. J Am Coll Cardiol 2013, 61:1539-1547.
79. Braunwald E Biomarkers in heart failure. N Engl J Med 2008, 358:2148-2159.
80. Lipshultz SE, Miller TL, Scully RE, et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol 2012, 30:1042-1049.
81. Lipshultz SE, Rifai N, Dalton VM, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 2004, 351:145-153.
82. Dolci A, Dominici R, Cardinale D, Sandri MT, Panteghini M Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use. Am J Clin Pathol 2008, 130:688-695.
83. Vasan RS, Benjamin EJ, Larson MG, et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA 2002, 288:1252-1259.
84. Murali S, Baldisseri MR Peripartum cardiomyopathy. Crit Care Med 2005, 33(suppl):S340-S346.
85. Grewal J, Siu SC, Ross HJ, et al. Pregnancy outcomes in women with dilated cardiomyopathy. J Am Coll Cardiol 2009, 55:45-52.
86. Stergiopoulos K, Shiang E, Bench T Pregnancy in patients with pre-existing cardiomyopathies. J Am Coll Cardiol 2011, 58:337-350.
87. Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail 2010, 12:767-778. the Heart Failure Association of the European Society of Cardiology Working Group on Peripartum Cardiomyopathy.
88. Silber JH, Cnaan A, Clark BJ, et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol 2004, 22:820-828.
89. Rosenthal D, Chrisant MR, Edens E, et al. International Society for Heart and Lung Transplantation: Practice guidelines for management of heart failure in children. J Heart Lung Transplant 2004, 23:1313-1333.
90. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009, 119:e391-e479.
91. De Caro E, Smeraldi A, Trocchio G, Calevo M, Hanau G, Pongiglione G Subclinical cardiac dysfunction and exercise performance in childhood cancer survivors. Pediatr Blood Cancer 2011, 56:122-126.
92. Hoffman MC, Mulrooney DA, Steinberger J, Lee J, Baker KS, Ness KK Deficits in physical function among young childhood cancer survivors. J Clin Oncol 2013, 31:2799-2805.
93. Gidding SS, Lichtenstein AH, Faith MS, et al. Implementing American Heart Association pediatric and adult nutrition guidelines: a scientific statement from the American Heart Association Nutrition Committee of the Council on Nutrition, Physical Activity and Metabolism, Council on Cardiovascular Disease in the Young, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Nursing, Council on Epidemiology and Prevention, and Council for High Blood Pressure Research. Circulation 2009, 119:1161-1175.
94. Smith SC, Collins A, Ferrari R, et al. Our time: a call to save preventable death from cardiovascular disease (heart disease and stroke). J Am Coll Cardiol 2012, 60:2343-2348. the World Heart Federation, the American Heart Associationthe American Heart Association, the American College of Cardiology Foundationthe American College of Cardiology Foundation, the European Heart Networkthe European Heart Network, the European Society of Cardiologythe European Society of Cardiology.
95. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2010, 122:e584-e636. the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
96. Meacham LR, Chow EJ, Ness KK, et al. Cardiovascular risk factors in adult survivors of pediatric cancer--a report from the childhood cancer survivor study. Cancer Epidemiol Biomarkers Prev 2010, 19:170-181.
97. Oeffinger KC, Adams-Huet B, Victor RG, et al. Insulin resistance and risk factors for cardiovascular disease in young adult survivors of childhood acute lymphoblastic leukemia. J Clin Oncol 2009, 27:3698-3704.
98. Oeffinger KC, Nathan PC, Kremer LC Challenges after curative treatment for childhood cancer and long-term follow up of survivors. Hematol Oncol Clin North Am 2010, 24:129-149.
99. Gagliardi G, Constine LS, Moiseenko V, et al. Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys 2010, 76(suppl):S77-S85.
100. Hancock SL, Tucker MA, Hoppe RT Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 1993, 270:1949-1955.
101. Colan SD, Shirali G, Margossian R, et al. The ventricular volume variability study of the Pediatric Heart Network: study design and impact of beat averaging and variable type on the reproducibility of echocardiographic measurements in children with chronic dilated cardiomyopathy. J Am Soc Echocardiogr 2012, 25:842-854. Pediatric Heart Network Investigators.
102. Colan SD, Parness IA, Spevak PJ, Sanders SP Developmental modulation of myocardial mechanics: age- and growth-related alterations in afterload and contractility. J Am Coll Cardiol 1992, 19:619-629.
103. Monsuez JJ Detection and prevention of cardiac complications of cancer chemotherapy. Arch Cardiovasc Dis 2012, 105:593-604.
104. Thavendiranathan P, Grant AD, Negishi T, Plana JC, Popović ZB, Marwick TH Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol 2013, 61:77-84.
105. Partington SL, Cheng S, Lima JA Cardiac magnetic resonance imaging for stage B heart failure. Heart Fail Clin 2012, 8:179-190.
106. Wong FL, Bhatia S, Landier W, et al. Cost-effectiveness of the children's oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure. Ann Intern Med 2014, 160:672-683.
107. Yeh JM, Nohria A, Diller L Routine echocardiography screening for asymptomatic left ventricular dysfunction in childhood cancer survivors: a model-based estimation of the clinical and economic effects. Ann Intern Med 2014, 160:661-671.
108. Armenian SH, Ding Y, Mills G, et al. Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation. Br J Haematol 2013, 163:205-213.
109. Visscher H, Ross CJ, Rassekh SR, et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol 2012, 30:1422-1428. the Canadian Pharmacogenomics Network for Drug Safety Consortium.